Ratings Surperformance

Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
-

Ratings ESG MSCI

Ratings Northwest Biotherapeutics, Inc.: Strengths and Weaknesses

Highlights: Northwest Biotherapeutics, Inc.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.

Rating Financials

Northwest Biotherapeutics, Inc. SectorGermany

Fundamentals

-

Growth

-

Revenue growth

-

EPS growth

-

FCF growth

-

Profitability

-

EBITDA Margin

-

EBIT Margin

-

Net Margin

-

Capital Efficiency

-

ROA

-

ROCE

-

ROE

-

Financial Health

-

Gearing

-

Leverage

-

Capital Intensity

-

Balance sheet growth

-

Long Term balance sheet growth

-

Long term revenue growth

-

Long term EPS growth

-
More ratings

Rating Valuation

Northwest Biotherapeutics, Inc. SectorGermany

Global Valuation

-

Enterprise Value

-

EV/Revenue

-

EV/EBITDA

-

EV/FCF

-

Equity Valuation

-

P/E

-

PBR

-

Dividend Yield

-

EV/EBIT

-

CAPEX/Revenue

-
More ratings

Rating Consensus

Northwest Biotherapeutics, Inc. SectorGermany

Consensus

Analysts' buy/sell recommendations

Analysts' recommendations evolution (1 year)

Analysts' recommendations evolution (4 months)

Analysts' target price

Analysts' target price evolution (1 year)

Analysts' target price evolution (4 months)

Analysts' recommendations evolution (7 days)

Target Price evolution (7 days)

More ratings

Rating Business Predictability

Northwest Biotherapeutics, Inc. SectorGermany

Visibility

-

Analysts' coverage

-

Financial estimates divergence

-

Analysts' recommendations divergence

Analysts' Target price divergence

-

Surprise rates

-

Rating Revisions

Northwest Biotherapeutics, Inc. SectorGermany

Financial revisions

-

Revenue revisions (1 year)

Revenue revisions (4 months)

EPS revisions (1 year)

-

EPS revisions (4 months)

-

EPS revisions (7 days)

-

Revenue revisions (7 days)

More ratings


Capi.($) Investor ESG MSCI Fundamentals Financial revisions Global Valuation Visibility Consensus
260M - - - - - -
71.81B
AAA
60.06B
A
27.93B
AAA
25.7B -
BBB
- -
24.89B - - - -
20.92B
A
15.04B
AA
14.46B
BB
13.87B
AA
Average 27.49B
AA
Weighted average by Cap.
AA
  1. Stock Market
  2. Stocks
  3. NWBO Stock
  4. NBYB Stock
  5. Ratings Northwest Biotherapeutics, Inc.